Abstract:e13508 Background: Murine double minute-2 (MDM2) has increasing clinic relevance as preclinical and early clinical evidences have showed that the MDM2 inhibitors are promising alternative treatments for patients with MDM2-amplified (-amp) and TP53-wild-type (-WT) tumors by preventing TP53 protein degradation. However, exploration into genomic landscape of MDM2/TP53 across various solid tumors in Chinese patients is still limited. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumor samples were collected from 10010 Chinese patients with solid tumors and subjected to a clinical-grade next-generation sequencing (NGS)-based 450 gene panel testing carried out by a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Genomic alterations (GAs) including single base substitutions, short and long insertion/deletions (Indels), copy number variations, gene fusions, and rearrangements were analyzed. Tumor mutational burden (TMB) was measured by a NGS algorithm. Results: Amplification of MDM2 occurred in 3.3% of Chinese patients. MDM2-amp was detected most frequently in soft tissue sarcoma (STS, 11.4 %), melanoma (10.3 %) and osteosarcoma (6.3 %). Notably, MDM2-amp was revealed to be mutually exclusive with TP53-mut in most tumor types other than esophageal carcinoma (93.9 %), head and neck carcinoma (68.4%) and ovarian carcinoma (50 %). Tumors with highest frequencies of MDM2-amp/ TP53-WT were melanoma (100%), osteosarcoma (100%) and urothelial carcinoma (100 %). The most common co-altered genes accompanied with MDM2-amp were FRS2 (84%), CDK4 (38%), EGFR (26%), TP53 (17%) and GLI1 (14%). 82.8% patients who had one or more co-alterations potentially targetable with either FDA-approved or investigational agent. Moreover, TMB of MDM2-amp tumors were significantly lower than that of MDM2-WT and MDM2-mutation (-mut) tumors (median TMB: 3.1 vs. 4.6 vs. 10.8, p < 0.001 respectively). Conclusions: MDM2 amplification was found in 3.3% of 10010 Chinese cancer patients, 83.4% of whom harbored wild-type TP53 that were potentially responsive to MDM2 inhibitors. In addition, 82.8% of the patients with MDM2-amp harbored genomic co-alterations and were potentially therapy targetable. This study provided insights into identifying patients who might potentially benefit from anti-MDM2 therapies.

RankDMG: a differentially methylated gene analysis method for three special scenarios

Tissue specific differentially methylated regions (TDMR): Changes in DNA methylation during development.

DMseg: a Python algorithm for de novo detection of differentially or variably methylated regions

HMM-DM: identifying differentially methylated regions using a hidden Markov model

Detection of differentially methylated CpG sites between tumor samples with uneven tumor purities.

Age-Adjusted Nonparametric Detection of Differential Dna Methylation with Case-Control Designs

Gbdmr: identifying differentially methylated CpG regions in the human genome via generalized beta regressions

Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm

Detecting Differentially Methylated Loci for Illumina Array Methylation Data Based on Human Ovarian Cancer Data.

Calling differentially methylated regions from whole genome bisulphite sequencing with DMRcate

A Hybrid Method Based on Beta-Binomial Bayesian Hierarchical Model and Combination of Ranking Method to Detect Differential Methylation Regions in Bisulfite Sequencing Data

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

09-05 FastDMA : an Infinium Humanmethylation 450 Beadchip Analyzer

A comprehensive comparison of residue-level methylation levels with the regression-based gene-level methylation estimations by ReGear

FastDMA: an Infinium HumanMethylation450 Beadchip Analyzer

A Statistical Method for Detecting Differentially Methylated Gene Functional Regions Based on Case-Control Studies

A novel method for detecting association between DNA methylation and diseases using spatial information

SurvivalMeth: a web server to investigate the effect of DNA methylation-related functional elements on prognosis

The Identification of Specific Methylation Patterns across Different Cancers

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancer

HMM-Fisher: identifying differential methylation using a hidden Markov model and Fisher’s exact test